HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies

International Immunopharmacology

Volumn 1, Issue 4, 2001, Pages 763-768

  Tian, Haijun ^a   Xiao, Yi ^a   Zhu, Mei ^a   Chen, Ying Hua ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Epitope vaccine; HIV 1; Immunogenicity; Neutralizing epitope

Indexed keywords

ADJUVANT; ALUMINUM; EPITOPE; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE; VIRUS PROTEIN;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; STRAIN DIFFERENCE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ALUM COMPOUNDS; AMINO ACID SEQUENCE; ANIMALS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; MOLECULAR SEQUENCE DATA; RABBITS;

EID: 0035108542     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00017-0     Document Type: Article

References (23)

1. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma
2. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
3. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
4. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
5. HIV type 1 coreceptors, neutralization serotypes, and vaccine development
6. Epitope-vaccine: A new strategy against HIV-1
7. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type I
8. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1
9. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
10. Characterization of immune suppression by a synthetic HIV gp41 peptide
11. A common epitope on gp41, IFN-α and IFN-β induces protective activity
12. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences
13. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection
14. A randomized, placebo-controlled, blind anti-AIDS clinical trial: Safety and immunogenicity of a specific anti-IFN immunization
15. Structure and polymorphism of HIV-1 third variable loops
16. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
17. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1
18. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1)
19. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
20. A strategy for rational design of fully synthetic glycopeptide conjugate vaccines
21. Viral persistence in vivo through selection of neutralizing antibody-escape variants
22. Immunological and Virological analyses of persons infected by Human-Immunodeficiency-Virus type-1 while participating in trials of recombinant gp120 subunit vaccines
23. Neutralizing antibodies: Mechanism of neutralization and protective activity against HIV-1